Safety and Efficacy of Concurrent Cisplatin and Radiotherapy in Inoperable or Metastatic Squamous Cell Esophageal Cancer

Between August 1996 and May 1999, 50 consecutive, previously untreated patients with carcinoma of the esophagus and who were inoperable for various reasons were treated with weekly doses of cisplatin (35 mg/m 2 , maximum 7 cycles) concurrent with either 66 Gy/33 fractions external beam radiotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2002, Vol.41 (5), p.457-462
Main Authors: Kumar, Shaleen, Dimri, Kislay, Datta, Niloy R., Rastogi, Neeraj, Lal, Punita, Das, Koilpillai J. Maria, Ayyagari, Sundar
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anemia - etiology
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - complications
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - radiotherapy
Cisplatin - adverse effects
Cisplatin - therapeutic use
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Deglutition Disorders - etiology
Deglutition Disorders - therapy
Disease Progression
Esophageal Neoplasms - complications
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - radiotherapy
Female
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Neutropenia - etiology
Pharmacology. Drug treatments
Radioisotope Teletherapy
Safety
Survival Analysis
Survival Rate
Treatment Outcome
Vomiting - etiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Between August 1996 and May 1999, 50 consecutive, previously untreated patients with carcinoma of the esophagus and who were inoperable for various reasons were treated with weekly doses of cisplatin (35 mg/m 2 , maximum 7 cycles) concurrent with either 66 Gy/33 fractions external beam radiotherapy (EBRT) (n=42) or 50 Gy/25 fractions EBRT and two insertions of high-dose-rate intraluminal radiotherapy of 6 Gy each, spaced a week apart (n=8). Eighty-two percent (41/50) of the patients received the stipulated radiotherapy (RT) dose. Seventy-six percent (38/50) received at least 6 cycles of chemotherapy. Neutropenia in the form of WHO grade II-12% (6/50) and grade III-2% (1/50) was observed. Grade III emesis was seen in 8% (4/50). Improvement in the swallowing status was seen in 84% (42/50). Median duration of dysphagia relief was 6 months. The median overall survival was 9 months with 17% estimated to be alive after 4 years. Combined treatment with single agent cisplatin and definitive radiotherapy for inoperable cancer of the esophagus is safe, well tolerated and reasonably efficacious.
ISSN:0284-186X
1651-226X
DOI:10.1080/028418602320405050